A new strategy for the treatment of heavily pretreated metastatic breast cancer - A case report and review of the literature

Sep 24, 2026

Uploaded by Fans

Breast cancer is a major global health problem, and treatment outcomes remain unsatisfactory for advanced metastatic disease, especially triple-negative cases. A case report describes a heavily pretreated patient with multiple metastases who achieved a good response and tolerability with a combination of utidelone and capecitabine. After 10 cycles, the patient maintained a progression-free survival of 10 months and remained in good general condition. The report concludes the combination provides a promising option for multi-drug resistant metastatic breast cancer.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages5

Reading Time13 min

AccessFree to download

Abstract

1. Introduction

2. Case presentation

Conclusion

Abbreviations

® Clinical Case Report A new strategy for the treatment of heavily pretreated metastatic breast cancer A case report and review of the literature Ting-Ting Ge, MMa ,b , Xiao-Juan Pan, MBa ,b , Xi-Meng Zuo, MMa , Xiao-Guang Shi, MBa ,* , Yu-Kun Wang, MMa , Ping Sun, MMa , Xiang Gao, MMa , Xue Feng, MMa , Shuang Gao, MMa , Tang-Shun Wang, MMa | Abstract
Background: Breast cancer is one of the most common type of cancers worldwide and remains a critical health issue. Although there are numerous treatment options for advanced metastatic breast cancer, the results are not satisfactory, particularly for triple-negative breast cancer. New treatment modalities need to be explored.
Case presentation: We present the case of a breast cancer patient with multiple metastases who achieved a good response and tolerance to the combination treatment of utidelone plus capecitabine. After being treated with 10 cycles of combined treatment, the patient is now in a good general condition with a progression-free survival time of 10 months.
Conclusion: To our knowledge, this is the first report of utidelone plus capecitabine successfully treating a patient with heavily pretreated metastatic breast cancer. This combined treatment offers a new option for patients with multi-drug resistant breast cancer.
Abbreviations: CARE = CAre REport guidelines, ER = estrogen receptor, HER-2 = humanepidermal growth factor receptor 2, OS = overall survival, PET-CT = positronemission tomography-computed tomography, PFS = progression-free survival, PR = progesterone receptor. | | --- | | Keywords: case report, heavily pretreated metastatic breast cancer, utidelone | 1. Introduction According to the Global Cancer Statistics 2020, female breast cancer is the most prevalent diagnosed tumor in the world.[1] Breast cancer has the highest incidence rate in China, with the number of new cases estimated to be around 410,000 per year, and the number of patients is also increasing yearly. Anthracyclines and taxanes are the first-line drugs for the treatment of breast cancer and are also the drugs of choice for advanced breast cancer. However, due to drug resistance, patients with advanced breast cancer who have received chemotherapy containing paclitaxel or anthracyclines have a certain probability of recurrence of metastasis within 1 year, and those who have failed the second-line treatment after metastasis are considered refractory breast cancer. There is no standard treatment protocol for advanced breast cancer after failing previous multiple lines of therapy. Metastatic breast cancer has a median survival rate of only 15 to 20 months. As a result, the effective treatment of advanced refractory breast cancer has become a challenge and a major issue in the current research field. Utidelone is an epothilone B derivative that induces apoptosis by promoting microtubule protein polymerization and stabilizing the microtubule structure. In vitro studies have demonstrated that utidelone inhibits the proliferation of breast cancer MCF-7, prostate cancer PC-3, hepatocellular carcinoma HepG2, and multidrug resistant tumor cell lines such as breast cancer NCI/ADR-Res, colon cancer LS1034, and colon cancer HCT15 . At the same time, the results of Phase 2 and Phase 3 clinical trials of utidelone indicated its enormous potential in the treatment of heavily pretreated, drug-resistant, and advanced metastatic breast cancer, bringing new hope to patients. We achieved encouraging results in treating patients with advanced breast cancer with utidelone plus capecitabine. The treatment and efficacy of a patient admitted to our hospital with advanced refractory breast cancer are presented below, and the relevant literature is reviewed to further discuss the value of utidelone TTG andXJP contributed equally to this work. The authors have no funding and conflicts of interest to disclose. The datasets generated during and/or analyzed during the current study are ava

FAQs

What treatment combination was used in the case report?

The patient received utidelone in combination with capecitabine.

How did the patient respond after treatment?

After 10 cycles of the combined therapy, the patient showed a good response and tolerability, with progression-free survival of 10 months.

Why is this report considered important for heavily pretreated metastatic breast cancer?

It presents what the authors describe as a first report of successful use of utidelone plus capecitabine in a heavily pretreated metastatic breast cancer case, offering a new option for multi-drug resistant disease.

Sep 24, 2026

Uploaded by Fans